The partnership aims to accelerate life sciences research and development.
Biotechnology companies Elegen and Integrated DNA Technologies (IDT) have partnered to offer early access to Elegen’s Enfinia Plasmid DNA to IDT customers.
“This collaboration allows Elegen to expand access to our Enfinia Plasmid DNA and equip researchers rapid access to longer and more complex DNA sequences—capabilities that have historically been limited in the market,” Elegen founder and CEO Dr Matthew Hill.
“We believe this partnership will accelerate research and development across the industry, driving innovation and breakthroughs in the life sciences.”
The Enfinia Plasmid DNA is a rapid clonal gene synthesis powered by inserts and standardised vectors. The long, high-complexity clonal gene synthesis service ships next-generation sequencing (NGS)-verified 5kb to 15kb clonal genes from Elegen’s US facility.
IDT customers can participate in an early access programme ahead of the full commercial launch.
